• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by ESAB Corporation

    5/30/25 4:28:00 PM ET
    $ESAB
    Industrial Machinery/Components
    Industrials
    Get the next $ESAB alert in real time by email
    SD 1 formsd2025.htm SD Document



    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM SD

    SPECIALIZED DISCLOSURE REPORT

    ESAB CORPORATION
    (Exact name of the registrant as specified in its charter)
    Delaware001-4129787-0923837
    (State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.)
    909 Rose Avenue, 8th Floor 20852
    North Bethesda, MD
    (Address of principal executive offices)(Zip code)

    Curtis E. Jewell, Senior Vice President, General Counsel and Secretary
    (301) 323-9099
    (Name and telephone number, including area code, of the person to contact in connection with this report.)

    Check the appropriate box to indicate the rule pursuant to which this Form is being submitted, and provide the period to which the information in this Form applies:

    ☒
    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.
    ☐
    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended ______.




    Section 1 – Conflict Minerals Disclosure

    Item 1.01 Conflict Minerals Disclosure and Report

    As provided for in Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and Form SD, a Conflict Minerals Report is provided as an exhibit to this Form SD and is available at the following Internet website: https://investors.esabcorporation.com/financials/sec-filings. The information contained on our website is not incorporated by reference into this Form SD or our Conflict Minerals Report and should not be considered part of this Form SD or the Conflict Minerals Report.

    Item 1.02 Exhibit

    The Conflict Minerals Report described in Item 1.01 is filed as Exhibit 1.01 to this Form SD.


    Section 2 – Resource Extraction Issuer Disclosure

    Item 2.01 Resource Extraction Issuer Disclosure and Report

    Not applicable.


    Section 3 – Exhibits

    Item 3.01 Exhibits
    Exhibit No.
    Exhibit
    1.01
    Conflict Minerals Report for the calendar year ended December 31, 2024





    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

    ESAB CORPORATION
    (Registrant)
    By:
    /s/ Curtis E. Jewell
    Date: May 30, 2025
    Name: Curtis E. Jewell
    Title: Senior Vice President, General Counsel and Secretary




    Get the next $ESAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ESAB

    DatePrice TargetRatingAnalyst
    4/1/2025$123.00 → $147.00Neutral → Buy
    UBS
    2/24/2025$122.00 → $120.00Underperform → In-line
    Evercore ISI
    12/12/2024$160.00Buy
    Jefferies
    11/18/2024$138.00 → $130.00Buy → Hold
    Stifel
    11/13/2024$102.00 → $122.00In-line → Underperform
    Evercore ISI
    6/20/2024$115.00Outperform
    Oppenheimer
    3/18/2024$111.00 → $125.00Neutral → Overweight
    JP Morgan
    9/27/2023$78.00Neutral
    UBS
    More analyst ratings